Danish biosolutions company Novonesis on Thursday raised its full-year sales forecast after reporting strong growth for the first nine months of the year, citing a robust performance across its markets.
The company said it now expects full-year organic sales growth of 7% to 8%, narrowing its previous guidance of 6% to 8%.
The updated outlook follows an 8% increase in organic sales for the nine-month period, which was driven by a 12% rise in emerging markets and 6% growth in developed markets.
Adjusted earnings before interest, taxes, depreciation, and amortization margin for the period was 37.3%, up 1.3 percentage points from a year earlier, despite what the company called significant currency headwinds.
“I am pleased with our performance in the first nine months, where we delivered 8% organic sales growth with solid profitability and cash flow,” President and CEO Ester Baiget said.
“We continue to successfully execute on our strategic priorities, positioning us firmly to deliver on our 2030 targets.”
Novonesis recently set new long-term goals, targeting an organic sales compound annual growth rate of 6-9% and an adjusted EBITDA margin of around 39% by 2030.
For the full year 2025, the company expects its adjusted EBITDA margin to be at the lower end of its 37% to 38% range.
More from this issuer
Related coverage
Novonesis on Wednesday laid out new long-term financial targets, aiming to accelerate sales growth and expand profit margins through 2030 as part of its new ‘GROW’ strategy.
Novonesis has successfully completed its acquisition of dsm-firmenich's share of the Feed Enzyme Alliance, the company announced.